

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/744,641	07/27/2001	Marc Pignot	11413-003001	3092
7:	590 09/26/2002			
Fish & Richardson			EXAMINER	
4350 La Jolla V San Diego, CA	/illage Drive Suite 500 92122		WEBER, JON P	
			ART UNIT	PAPER NUMBER
			1651	
			DATE MAILED: 09/26/2002	/0

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·		Application N .	Applicant(s)				
Office Action Summary		09/744,641	PIGNOT ET AL.				
		Examiner	Art Unit				
		Jon P. Weber, Ph.D.	1651				
The MAILING DATE f this c mmunication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)	Responsive to communication(s) filed on						
2a)□	· · · · · · · · · · · · · · · · · · ·	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims		,				
4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.						
6)□	6)☐ Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) 1-30 are subject to restriction and/or election requirement.							
Applicati	ion Papers						
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)[The proposed drawing correction filed on		sapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)	☑ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority document	s have been received.					
	2. Certified copies of the priority document	s have been received in App	plication No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice 2) Notice	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Inf	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)				

Application/Control Number: 09/744,641

Art Unit: 1651

Status of the Claims

Claims 1-30 have been presented for examination.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-8, 15, 18-19, drawn to an aziridine compound.

Group II, claim(s) 9-14, 16-19, drawn to a complex of an aziridine compound and a methyltransferase.

Group III, claim(s) 20-29, drawn to a method of modifying a target molecule with an aziridine and a methyltransferase.

Group IV, claim(s) 30, drawn to a modified molecule.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, II and IV are each drawn to distinct products that do not share a special technical feature. Group I is a family of aziridine compounds, Group II is a complex of the compounds with methyltransferases. Depending on the enzyme, the complex may involve covalent complex and transfer to an enzyme nucleophile to form a modified enzyme. Other

enzymes whose mechanisms involve SN2 direct transfer may have a modified intermediate. Group IV has had part of the aziridine compound transferred to the acceptor. Group III is a method of making the product of Group IV.

In addition, this application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- a) aziridine compounds
- b) methyltransferases
- c) target molecules
- d) modified target molecules

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

- a) aziridine compounds (if Groups I-III are elected)
- b) methyltransferases (if Groups II-III) are elected)
- c) target molecules (if Group III is elected)
- d) modified target molecules (if Group IV is elected)

The following claim(s) are generic: 1, 9, 20 and 30.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: there is no technical feature linking these different species between each other. Within species (a), the compounds have an extremely wide range of possible modifications; within species (b) the enzymes have diverse target molecules from DNA to catecholamines; within (c) and (d) the targets and modified targets are quite diverse as indicated under item (b).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/744,641 Page 5

Art Unit: 1651

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon P. Weber, Ph.D. whose telephone number is 703-308-4015. The examiner can normally be reached on daily, off 1st Fri, 9/5/4.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 703-308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703,30%-0096.

Yon P. Weber, Ph.D Primary Examiner Art Unit 1651

JPW September 23, 2002